logo-loader
viewOpiant Pharmaceuticals

Opiant Pharmaceuticals' advisory board to meet

Pharma group Opiant Pharmaceuticals is to convene its medical advisory board to discuss its development programmes in substance use, addictive and eating disorders, it told investors.

BigBoardRoom_56c48134e792a.jpg
“The medical advisory board meeting is an important step in the process of moving our clinical programs forward,” said Roger Crystal, managing director and chief executive of Opiant.

Pharma group Opiant Pharmaceuticals (OTCQB:LLTP) is to convene its medical advisory board to discuss its development programmes in substance use, addictive and eating disorders, it told investors.

“The medical advisory board meeting is an important step in the process of moving our clinical programs forward,” said Roger Crystal, managing director and chief executive of  Opiant.

“We are delighted to have the engagement of world leaders in their respective fields, and we look forward to their input."

More than 45 million people have one of the disorders above.

The firm has what's called opioid antagonist nasal delivery technology and says it's positioned to become a leader in these treatment markets.

Its first product, NARCAN Nasal Spray, is approved for marketing in the USA by the company’s partner, Adapt Pharma.

Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near term focus on cocaine use disorder and binge eating disorder (BED).

Quick facts: Opiant Pharmaceuticals

Price: 8.92 USD

NASDAQ:OPNT
Market: NASDAQ
Market Cap: $37.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tony Locantro says mining stocks best way to play rising gold price

Alto Capital's Tony Locantro warns investors that stock markets are in danger of breaking away from economic reality. Pip trading madness is seeing stocks rise 1,000% in a day on nothing, he adds, saying it’s a bubble and people should steer clear of it. Gold stocks, meanwhile, are the best way...

4 hours, 54 minutes ago

2 min read